|05th December,2018||11:00-12:30||Track 1|
What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence for patients on public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?